ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "370: Pharma sours on the U.K., plus biotech M&A's quiet roll"
Episode Synopsis
STAT's European correspondent Andrew Joseph calls in from the U.K. to the podcast to dissect why companies like Merck and GSK are putting their money elsewhere.
We also discuss the Advisory Committee on Immunization Practices, or ACIP, meeting and biotech M&A, including Roche's $3.5 billion acquisition of 89bio and its MASH drug, announced this week.
We also discuss the Advisory Committee on Immunization Practices, or ACIP, meeting and biotech M&A, including Roche's $3.5 billion acquisition of 89bio and its MASH drug, announced this week.
More episodes of the podcast The Readout Loud
382: Biotech's year in review
18/12/2025
In God we trust